Sofwave Medical Overview
Sofwave Medical specializes in non-invasive aesthetic medical solutions to improve skin laxity, provide lifting effects, and enhance muscle toning. Utilizing its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™), the Sofwave product delivers controlled ultrasound energy to the mid-dermal layer, stimulating collagen and elastin production and improving skin appearance with minimal downtime. Clinically validated and supported by multiple broad FDA clearances, Sofwave's technologies offer effective solutions for patients seeking aesthetic enhancements without invasive procedures. The introduction of the Pure Impact add-on module expands Sofwave's product portfolio, offering increased treatment versatility and efficiency to address a broader range of aesthetic concerns. Pure Impact is the world’s first plyometric muscle activation and toning device, emulating complex, compound full-body muscle movements. Sofwave Plus Pure Impact is the ultimate complement to GLP-1 weight loss drugs. As these medications help with weight loss, Sofwave + Pure Impact ensures no muscle loss, increased tone, and decreased overall laxity, providing a comprehensive solution for enhancing physical appearance and health. Backed by strong clinical data and regulatory endorsements, Sofwave Medical represents a significant opportunity for investors in a rapidly growing market segment.
Cumulative Funding Raised Over Time ($)
$8.4MAug 2019
Latest News
growth-positive
Sofwave to Participate in Upcoming November Investor Conferences
SofWave Medical, Ltd., a leader in non-invasive aesthetic medical devices, announced its participation in several upcoming investor conferences. The company will present at the Stifel 2025 Healthcare Conference, Jefferies London Healthcare Conference, and Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in November 2025. SofWaves innovative technology, SUPERB™, is FDA-cleared for improving facial lines, wrinkles, and other aesthetic concerns. The companys products offer effective and safe solutions for aesthetic treatments, enhancing its growth potential. The participation in these conferences is expected to bolster investor interest and highlight the companys advancements in the aesthetic medical device sector.
growth-positive
Sofwave to Participate in the Jefferies Virtual Private MedTech Summit
SofWave Medical, Ltd., a leader in energy-based non-invasive aesthetic medical devices, announced its participation in the Jefferies Virtual Private MedTech Summit on October 1st, 2025. The company has developed innovative technology for wrinkle reduction, lifting, and cellulite treatment using its FDA-cleared SUPERB™ technology. SofWaves products, including the Pure Impact™ module for muscle toning, offer effective and safe aesthetic solutions. The participation in the summit highlights the companys growth and innovation in the MedTech sector.
growth-positive
Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming
SofWave Medical, Ltd. has launched the Pure Impact VIP™, a standalone device that extends its Pure Impact™ product line. This new device, which has received 510(k) premarket notification clearance from the FDA, offers comprehensive muscle strengthening programs targeting multiple body areas. The Pure Impact VIP™ is designed to enhance practice workflow and treatment flexibility, allowing simultaneous treatment of six muscle groups. The launch responds to customer demand for a system that can be used alongside Sofwaves existing products. The device is expected to meet the growing demand for aesthetic treatments, particularly among new patients concerned with skin laxity.
Product StageFDA approved/pending approvalCustomers
growth-positive
Sofwave to Participate in 10th Annual Needham Virtual MedTech & Diagnostics Conference
SofWave Medical, Ltd., a leader in non-invasive aesthetic medical devices, announced its participation in the 10th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference. The company, known for its innovative SUPERB™ technology, offers FDA-cleared solutions for wrinkle reduction, skin lifting, and cellulite improvement. Their products, including the Pure Impact™ module for muscle toning, provide effective and safe aesthetic solutions. The participation in the conference highlights the companys growth and engagement with the medical technology community.
growth-positive
Sofwave Medical Reports Record Second Quarter and First Half 2025 Financial Results and Business Highlights
SofWave Medical, Ltd. reported a record quarterly revenue of $21 million for Q2 2025, marking a 43% year-over-year growth. The company also achieved a recurring revenue of $9.2 million, a 53% increase from the previous year. With a gross margin of 75.5% and a net income of $1.5 million, SofWave is showing strong financial performance. The company has completed over 600,000 treatments and has over 1 million social media followers, indicating strong brand presence. SofWaves range of FDA-cleared products for various aesthetic treatments is driving industry adoption and customer loyalty. The company is well-positioned for continued growth and profitability with a scalable infrastructure.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $58.4M |
| Last funding | $50M |
| Stage | Public |
| Rounds | 2 |
| Investors | 3 |
Team Members
7
Employees: 51-200
Web & Social Links
| Website | sofwave.com |
| Careers | Careers page |
Locations
Yokneam Illit, Israel
California, USA
14331 Chambers Road, Tustin, California 92780, USA
Photos & Videos
5 item(s)
Sofwave Medical Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesAesthetic DevicesTarget Customer
Healthcare & Life SciencesLife SciencesCosmeticsHealthcareProvidersPatientsCore Technology
Simulation & ImagingUltrasoundTags (8)
clinicsmedical-technologieshealthcare-providersskin-carenon-invasivetreatmentsultrasoundmedical-devicesGeographic Markets
North AmericaAfricaEastern EuropeMiddle AfricaGlobalWest AsiaSouthern AfricaNorthern AfricaOceaniaAmericasEuropeSouthern EuropeNorthern EuropeCentral AsiaNorth AsiaSoutheast AsiaSouth AmericaWestern EuropeAsiaCentral AmericaSouth AsiaEast AsiaSofwave Medical Financials
$58.4M
Total funding
Undisclosed
Capital raised
$50M
Last funding
Public
Funding stage
2
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$8.4MAug 2019
Private Equity Funding
Undisclosed Round
Aug 2019
$8.4M
XT Venture Capital (Lead)
,
Dr. Shimon Eckhouse, Alon MedTech Ventures
Public Offering / Exit
POEvent
May 2021
Undisclosed
Sofwave Medical Lifecycle
Cumulative Funding Raised Over Time
$8.4MAug 2019
All Events
Undisclosed Round
Aug 2019
$8.4M
XT Venture Capital (Lead)
,
Dr. Shimon Eckhouse, Alon MedTech Ventures
POEvent
May 2021
Undisclosed
Sofwave Medical News
72 articles
growth-positive
Sofwave to Participate in Upcoming November Investor Conferences
SofWave Medical, Ltd., a leader in non-invasive aesthetic medical devices, announced its participation in several upcoming investor conferences. The company will present at the Stifel 2025 Healthcare Conference, Jefferies London Healthcare Conference, and Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in November 2025. SofWaves innovative technology, SUPERB™, is FDA-cleared for improving facial lines, wrinkles, and other aesthetic concerns. The companys products offer effective and safe solutions for aesthetic treatments, enhancing its growth potential. The participation in these conferences is expected to bolster investor interest and highlight the companys advancements in the aesthetic medical device sector.
growth-positive
Sofwave to Participate in the Jefferies Virtual Private MedTech Summit
SofWave Medical, Ltd., a leader in energy-based non-invasive aesthetic medical devices, announced its participation in the Jefferies Virtual Private MedTech Summit on October 1st, 2025. The company has developed innovative technology for wrinkle reduction, lifting, and cellulite treatment using its FDA-cleared SUPERB™ technology. SofWaves products, including the Pure Impact™ module for muscle toning, offer effective and safe aesthetic solutions. The participation in the summit highlights the companys growth and innovation in the MedTech sector.
growth-positive
Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming
SofWave Medical, Ltd. has launched the Pure Impact VIP™, a standalone device that extends its Pure Impact™ product line. This new device, which has received 510(k) premarket notification clearance from the FDA, offers comprehensive muscle strengthening programs targeting multiple body areas. The Pure Impact VIP™ is designed to enhance practice workflow and treatment flexibility, allowing simultaneous treatment of six muscle groups. The launch responds to customer demand for a system that can be used alongside Sofwaves existing products. The device is expected to meet the growing demand for aesthetic treatments, particularly among new patients concerned with skin laxity.
Product StageFDA approved/pending approvalCustomers
growth-positive
Sofwave to Participate in 10th Annual Needham Virtual MedTech & Diagnostics Conference
SofWave Medical, Ltd., a leader in non-invasive aesthetic medical devices, announced its participation in the 10th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference. The company, known for its innovative SUPERB™ technology, offers FDA-cleared solutions for wrinkle reduction, skin lifting, and cellulite improvement. Their products, including the Pure Impact™ module for muscle toning, provide effective and safe aesthetic solutions. The participation in the conference highlights the companys growth and engagement with the medical technology community.
growth-positive
Sofwave Medical Reports Record Second Quarter and First Half 2025 Financial Results and Business Highlights
SofWave Medical, Ltd. reported a record quarterly revenue of $21 million for Q2 2025, marking a 43% year-over-year growth. The company also achieved a recurring revenue of $9.2 million, a 53% increase from the previous year. With a gross margin of 75.5% and a net income of $1.5 million, SofWave is showing strong financial performance. The company has completed over 600,000 treatments and has over 1 million social media followers, indicating strong brand presence. SofWaves range of FDA-cleared products for various aesthetic treatments is driving industry adoption and customer loyalty. The company is well-positioned for continued growth and profitability with a scalable infrastructure.
growth-positive
Sofwave to Participate in Jefferies Global Healthcare Conference
SofWave Medical, Ltd., a leader in energy-based non-invasive aesthetic medical devices, announced its participation in the Jefferies Global Healthcare Conference in New York from June 3-5, 2025. The companys CFO, Assaf Korner, will provide a corporate overview and engage in one-on-one investor meetings. SofWaves innovative technology, including the FDA-cleared SUPERB™ and Pure Impact™ modules, offers effective solutions for wrinkle reduction, muscle toning, and cellulite improvement. The companys participation in the conference is expected to enhance its visibility among investors and stakeholders in the healthcare sector.
growth-positive
Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights
SofWave Medical, Ltd. reported a strong first quarter for fiscal year 2025, with a 26% year-over-year revenue growth to $16.7 million. The company achieved a significant milestone by obtaining regulatory clearance in Japan, opening new opportunities in the APAC region. Recurring revenue increased by 49% year-over-year, now making up 42% of total revenue. The launch of the LiftHD™ body applicator has been well-received, further establishing SofWaves leadership in non-invasive regenerative aesthetics. The company is focused on growth and innovation, with a strategic vision to lead in the non-invasive energy-based regenerative medicine space.
Product StageCustomers
growth-positive
Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025
SofWave Medical, Ltd. announced the launch of its new liftHD body applicator at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025. This new device is designed for non-invasive aesthetic body treatments, improving cellulite and skin laxity appearance. The liftHD applicator uses the companys SUPERB™ pulse technology, offering broader, higher density thermal zones, reducing treatment time by approximately 40%. The launch is part of SofWaves strategy to expand its product line and meet the growing demand for non-invasive treatments. The company showcased its products at the ASLMS event, highlighting its commitment to innovation in aesthetic medical devices.
Product Stage
growth-positive
Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region
Sofwave Medical Ltd., a leader in non-invasive aesthetic medical devices, has received approval from Japans Pharmaceuticals and Medical Devices Agency to market its SUPERB™ Technology in Japan. This approval marks a significant expansion for Sofwave in the APAC region, which includes major markets like Japan, Australia, Taiwan, and South Korea. The company aims to leverage this opportunity to increase device sales and brand awareness, driven by the demand for minimally invasive procedures and an aging population. Sofwaves strategy includes a robust distribution network and marketing efforts across various media channels. The companys technology is FDA-cleared for several aesthetic applications, enhancing its market position.
Product StageCustomers
growth-positive
Sofwave to Participate in Upcoming Conferences
Sofwave Medical Ltd, a leader in non-invasive aesthetic medical devices, announced its participation in two upcoming conferences: the 24th Annual Needham Virtual Healthcare Conference and the Wells Fargo 2025 Virtual Private MedTech Symposium, both scheduled for April 9, 2025. The company specializes in wrinkle reduction and lifting using its FDA-cleared SUPERB™ technology, which is effective for improving facial lines, lifting eyebrows, and treating cellulite and acne scars. Additionally, their Pure Impact™ module, which uses 4th generation EMS technology, is cleared for muscle toning. This participation is expected to enhance the companys visibility and growth prospects.
growth-positive
Sofwave Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SofWave Medical, Ltd. reported strong financial results for the fourth quarter and full fiscal year 2024, with significant revenue growth and improved operating margins. The company achieved a 20% year-over-year revenue increase in the fourth quarter and a 19% increase for the full fiscal year. Recurring revenue saw a notable 79% year-over-year growth. Despite a challenging macroeconomic environment, SofWave is nearing breakeven with a narrowed operating loss and a non-IFRS operating profit. The company has a lean infrastructure to support continued growth and profitability, backed by FDA clearances and a growing social media presence.
growth-positive
Sofwave Medical Reports Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2024 Topline Financial Results
Sofwave Medical Ltd., a leader in non-invasive aesthetic medical devices, reported preliminary financial results for Q4 and the full fiscal year ending December 31, 2024. The company expects Q4 revenue to be between $18.2 million and $18.4 million, marking a 20% increase from the previous year. Full fiscal year revenue is projected to be between $59.5 million and $59.7 million, reflecting a 19% increase. Sofwaves innovative technology, including the FDA-cleared SUPERB™ and Pure Impact™ modules, continues to drive growth. The companys cash and cash equivalents stood at $21.6 million as of December 31, 2024. These results underscore Sofwaves strong market position and growth trajectory in the aesthetic medical device sector.
growth-positive
Sofwave Medical Reports Third Quarter 2024 Financial Results and Business Highlights
SofWave Medical, Ltd., a leader in non-invasive aesthetic medical devices, reported strong financial results for the third quarter and first nine months of 2024. The company achieved a 10.5% year-over-year revenue growth in the third quarter, with recurring revenue increasing by 72%. For the first nine months, revenue grew by 18%, and recurring revenue rose by 88%. The company also reported a significant reduction in operating losses and generated positive cash flow. CEO Louis Scafuri attributed the success to SofWaves superior business model, expanding brand awareness, and delivering excellent patient results. The company continues to navigate challenging market conditions while maintaining strong financial performance.
growth-positive
Sofwave to Participate in Stifel 2024 Healthcare Conference
Sofwave Medical Ltd, a leader in non-invasive aesthetic medical devices, announced that its CEO, Louis Scafuri, and CFO, Assaf Korner, will present a corporate overview at the Stifel 2024 Healthcare Conference in New York on November 19, 2024. The company specializes in innovative wrinkle reduction and lifting technologies, including its FDA-cleared SUPERB™ technology for improving facial lines and skin laxity. Sofwaves products offer effective and safe aesthetic solutions for physicians. The presentation aims to provide insights into the companys growth and technological advancements.
growth-positive
Dr. Kavita Darji Wins the Drs. Alastair and Jean D. Carruthers Award at ASDS 2024 for Sofwave SUPERB™ Abstract
Sofwave Medical Ltd, a leader in non-invasive aesthetic medical devices, announced that Dr. Kavita Darjis research abstract on their Synchronous Ultrasound Parallel Beam Technology was awarded the 2024 Drs. Alastair and Jean D. Carruthers Award at the ASDS annual meeting. The study demonstrated significant improvements in patients appearance after treatments, with 93% showing improvement at 1- and 3-month intervals. The technology, known as SUPERB™, targets the mid-dermis to enhance collagen production and skin elasticity. Sofwave CEO Louis Scafuri highlighted the growing market acceptance of their treatments. The award underscores Sofwaves commitment to advancing cosmetic dermatology through innovative technology.
growth-positive
Sofwave Obtains U.S. Patent for Fat Tissue Reduction Technology
SofWave Medical Ltd., a company specializing in non-invasive aesthetic medical devices, announced that it has been granted a new patent by the U.S. Patent and Trademark Office. The patent covers a system for treating fat tissue using unfocused ultrasound energy, which heats the fat tissue in the hypodermis layer while a cooling mechanism protects the skin surface. This development is expected to enhance SofWaves product offerings, which already include FDA-cleared technologies for wrinkle reduction, skin lifting, and cellulite improvement. The companys innovative approach provides effective and safe aesthetic solutions for physicians and their patients.
growth-positive
Sofwave to Participate in the Jefferies Virtual Private MedTech Summit
SofWave Medical Ltd, a leader in non-invasive aesthetic medical devices, announced that its CEO Louis Scafuri and CFO Assaf Korner will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Private MedTech Summit. The event will be held virtually from October 2-3, 2024. SofWave Medical specializes in innovative wrinkle reduction and lifting technologies, including the FDA-cleared SUPERB™ technology for facial lines, wrinkles, and cellulite treatment. The company aims to offer effective and safe aesthetic solutions for physicians and their patients.
Investment
growth-positive
Sofwave Names Larry Laber, Aesthetic Energy-Based Device Sales Veteran, to Role of Executive Vice President, North American Sales
SofWave Medical Ltd., a leader in energy-based non-invasive aesthetic medical devices, announced the appointment of Larry Laber as Executive Vice President of North American Sales on September 4, 2024. Laber, a veteran in the aesthetic energy-based medical device sales industry, will manage and expand the US sales team and align the go-to-market strategy with Canadian partner XCite Medical. Labers extensive experience and proven track record in increasing revenue and market share are expected to drive SofWaves growth. The company has recently introduced the Pure Impact™ non-invasive muscle toning module, enhancing its product offerings.
Management ChangesPartners
growth-positive
Sofwave Receives FDA Clearance for Pure Impact™ in Strengthening and Firming of Arms in the U.S.
SofWave Medical Ltd has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA) to expand the use of Pure Impact™ in strengthening and improvement in muscle tone and firmness sculpting of the arms. The launch of Pure Impact™ Arms will be supported by the “Sofwave Endless Summer” marketing campaign. The companys CEO, Louis Scafuri, believes that this is a major step towards achieving total body muscle activation harnessing the power of their PlyoPulse™ electric muscle stimulation technology.
CustomersExpand
Growth-Positive
Sofwave to Participate in 9th Annual Needham Virtual MedTech & Diagnostics Conference
SofWave Medical Ltd, a company specializing in non-invasive, aesthetic medical devices, has announced that its CEO, Louis Scafuri, and CFO, Assaf Korner, will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 12 – 13, 2024. The companys proprietary technology, SUPERB™, is FDA-cleared for improving facial lines and wrinkles, lifting the eyebrow and lax submental tissue, and treating acne scars. It also offers a Pure Impact™ module for muscle toning.
Management Changes
growth-positive
Sofwave Medical Reports Second Quarter and First Half 2024 Financial Results and Business Highlights
SofWave Medical Ltd reported its Q2 and H1 2024 financial results, showing a year-over-year growth of 18% and 22% respectively. The companys recurring revenue also increased by 83% year-over-year. The companys operating loss has continued to decrease, with a YoY decrease of 66% and 80% for IFRS and Non-IFRS respectively. The company expects to achieve operating break-even in 2024. The companys CEO, Louis Scafuri, expressed satisfaction with the financial results and operational performance, attributing the success to the additional Practice Development Managers who assist customers in the field.
Customers
growth-positive
Sofwave Medical Receives Marketing Clearance in Canada for Pure Impact™ Strength and Muscle Toning Device
SofWave Medical Ltd has received marketing clearance from Health Canada to commercialize its Pure Impact product utilizing PlyoPulse Electric Muscle Stimulation technology in Canada. The product, which is also approved and marketed in the U.S., is a muscle toning and firming system designed to stimulate multiple muscle groups and body areas simultaneously. The approval allows SofWave to launch its second Pure Impact product in North America, following a successful launch in the U.S.
CustomersExpand
growth-positive
Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights
SofWave Medical Ltd reported a 27% year-over-year growth in its first quarter revenue of 2024, amounting to $13.2M. The companys recurring revenue also increased by 118% year-over-year to $4.7M. The companys operating loss has narrowed to -$1.0M and -$0.4M for IFRS and non-IFRS, respectively. The company also launched Pure Impact™, a strength and muscle toning body module utilizing PlyoPulse™ EMS technology. The company aims to achieve operational break-even in 2024.
Customers
growth-positive
Sofwave Medical to Participate in the Needham 23rd Annual Healthcare Conference
SofWave Medical Ltd, a company specializing in energy-based non-invasive aesthetic medical devices, announced that its CEO, Louis Scafuri, and CFO, Assaf Korner, will provide a corporate update and participate in one-on-one investor meetings at the Needham 23rd Annual Healthcare Conference. The conference will be held virtually from April 8-11, 2024. SofWave Medical has developed a proprietary technology, SUPERB™, which is FDA-cleared to improve facial lines and wrinkles.
Management Changes
growth-positive
Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SofWave Medical, Ltd. reported a 41% year-over-year growth in full fiscal 2023 revenue, amounting to $50.3M. The companys recurring revenue also increased by 81% to $13.0M. The companys operating loss narrowed to -$0.2M in the fourth quarter, nearing breakeven. The companys CEO, Louis Scafuri, expressed satisfaction with the performance and highlighted the high customer satisfaction rate associated with their SUPERB™ technology. The company also appointed James Bartholomeusz to the newly created position of Chief Innovation Officer.
Customers
growth-positive
Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting
SofWave Medical Ltd, a leader in energy-based non-invasive, aesthetic medical devices, has announced its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting. Dr. Gilly Munavalli will present Sofwave’s new Pure Impact™ Strength and Muscle Toning module to fellow dermatologists and meeting participants for the first time in the United States. The companys technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue and the short term improvement in the appearance of cellulite.
CustomersExpand
growth-positive
Sofwave Medical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
SofWave Medical Ltd, a company specializing in non-invasive aesthetic medical devices, has announced that its CEO, Louis Scafuri, and CFO, Assaf Korner, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The conference will be held virtually on March 13, 2024. SofWave Medical has developed a proprietary technology, SUPERB™, which is FDA-cleared for the improvement of facial lines and wrinkles, lifting of the eyebrow and lax submental tissue, and treatment of acne scars.
Management Changes
growth-positive
Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer
SofWave Medical Ltd has appointed James Bartholomeusz as its new Chief Innovation Officer. Bartholomeusz, a medical aesthetics expert with over 20 years of experience, will lead global product innovation, development, and go-to-market strategies for new product launches. He previously served as chief technology officer at Lutronic, where he developed and executed a 5-year product roadmap and growth strategy. The appointment comes as SofWave seeks to accelerate growth, product innovation, and global expansion.
Management ChangesExpand
growth-positive
Sofwave Medical Receives 510(k) Marketing Clearance for Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology
SofWave Medical Ltd has received clearance from the U.S. Food and Drug Administration (FDA) for its Pure Impact device, which uses PlyoPulse electromagnetic stimulation technology. The device is an add-on to SofWaves existing medical aesthetic device platform and allows practitioners to expand their services. The approval allows SofWave to expand its medical aesthetic treatment beyond its existing SUPERB platform. The company plans to launch the product in the U.S. soon and is working to bring it to other geographies.
CustomersExpand
growth-positive
Sofwave Medical Receives FDA Clearance of SUPERB™ Technology For Improvement of the Appearance of Skin Laxity on the Upper Arm
SofWave Medical Ltd has received FDA clearance for its 510(k) premarket notification submission for the improvement of the appearance of skin laxity on the upper arms. The clearance is supported by a clinical study that showed 93% of treated arms were improved or very much improved in appearance. The companys SUPERB technology offers a noninvasive alternative to surgical arm lift procedures. The clearance paves the way for Sofwave to expand into additional treatment indications.
CustomersExpand
growth-positive
סופווייב קיבלה אישור FDA למודול טיפול גוף חדש שפיתחה
Medical aesthetic device company Sofwave has received FDA approval for its new Pure Impact module, which uses electrical stimulation for muscle toning and strengthening. The approval paves the way for Sofwave to expand its range of aesthetic medical treatments. The Pure Impact module can be used in conjunction with the companys SUPERB system or as a standalone treatment. The FDA approval follows several other approvals for the companys SUPERB platform, including for the improvement of acne scars, short-term cellulite appearance improvement, non-invasive treatment for facial and neck wrinkles, and additional indications for eyebrow lifting and lax submental tissue lifting.
CustomersExpand
growth-positive
Sofwave Earns Frost & Sullivan's 2023 North American Technology Innovation Leadership Award for Developing a Sophisticated Skin Tightening Ultrasound Technology with Minimal Downtime
Sofwave, a leading aesthetic device company, has been recognized with the 2023 North American Technology Innovation Leadership Award by Frost & Sullivan for its non-invasive skin-tightening technology, SUPERB. The technology uses a high-intensity parallel beam ultrasound to treat skin laxity without causing discomfort or injury to the patient. The device is FDA-cleared to treat brow and neck wrinkles, perform submental lift, and reduce cellulite. Sofwave has also recently received FDA clearance for acne scar reduction. The company is expanding its focus to body contouring applications and is growing its presence in Europe, the Middle East, Africa, and Asia-Pacific.
CustomersExpand
growth-positive
Sofwave Medical Reports Third Quarter 2023 Financial Results and Business Highlights
SofWave Medical, Ltd. reported a 49% year-over-year growth in its third quarter revenue, reaching $12.2M. The companys pulse recurring revenue also increased by 99% year-over-year to $3.1M. For the first nine months, the companys revenue was $35.0M, a 60% year-over-year growth. The companys operating loss significantly narrowed to $1.2M in the third quarter of 2023 compared to $5.2M in the same period the previous year. The companys CEO, Louis Scafuri, attributed the growth to the increasing adoption of SofWaves SUPERB™ technology and the effectiveness of their go-to-market strategy.
Customers
growth-positive
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars
SofWave Medical has received FDA clearance for its SUPERB™ system to be used for the treatment of acne scars. The company conducted a clinical study with 67 participants, where 97% of the treated subjects showed improvement in the appearance of acne scars. The global market value for acne scarring treatment is expected to reach $4.9 billion by 2029. SofWaves technology has already been cleared for use in non-invasive dermatological aesthetic treatments. The company plans to expand its regulatory approvals for additional medical aesthetic treatment indications.
Customers
growth-positive
Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights
SofWave Medical Ltd reported a 53% year-over-year growth in its second quarter revenue, amounting to $12.4M. The companys first half revenue also increased by 67% year-over-year, reaching $22.8M. The operating loss has significantly narrowed in both the second quarter and first half periods, moving the company closer to reaching operating break-even. Over 155,000 treatments have been performed since initial approval. The companys CEO, Louis Scafuri, expressed satisfaction with the performance and stated that the company is on a solid path towards reaching operating break-even and profitability.
Customers
Sofwave Medical Reports First Quarter Fiscal 2023 Financial Results and Recent Business Highlights
growth-positive
Sofwave™ Wins Good Housekeeping Magazine Award for Best Anti-Aging Pro Treatment
SofWave Medical has been named the winner of the Good Housekeeping Magazine Award for Best Anti-Aging Pro Treatment. The award recognizes Sofwaves non-invasive ultrasound technology as a superior innovative treatment. Sofwaves ultrasound technology, SUPERB, utilizes a novel approach to deep dermal heating, improving the appearance of fine lines, wrinkles, and skin laxity. The treatment is non-invasive, requires no downtime, and is suitable for all skin types. SofWave Medical is honored to receive the award and is committed to developing safe and effective treatments for aesthetic goals.
Customers
Sofwave™ Wins 2023 NewBeauty Award For Best Non-Invasive Cellulite Treatment
growth-positive
Sofwave™ Granted FDA Clearance For Latest Innovation: The "Precise" SUPERB™ Applicator
SofWave Medical Ltd has received FDA clearance for its Precise compact SUPERB™ applicator, which improves facial lines and wrinkles, lifts the eyebrow, and lifts lax submental and neck tissue. The applicator is also cleared for short-term improvement in the appearance of cellulite. The compact applicator head offers more convenient and precise treatment of smaller curved areas, such as around the eyes and mouth. The clearance is expected to be well-received by SofWave customers, and the company plans to leverage the new applicator in additional indications in the future.
CustomersPartners
growth-positive
Sofwave™ Granted FDA Clearance For Latest Innovation: The “Precise” SUPERB™ Applicator
SofWave Medical Ltd has announced the receipt of U.S. Food and Drug Administration (FDA) clearance for its Precise compact SUPERB applicator. The applicator is designed to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental and neck tissue. It is also FDA cleared for short-term improvement in the appearance of cellulite. The compact applicator delivers the same safe and effective Synchronous Ultrasound Parallel Beam technology of existing large size applicators, but has been further refined for more precise and convenient delivery of pulses around small, curved areas.
Customers
Sofwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Sofwave Medical to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Sofwave Gains Market Approval For SUPERB™ Non-Invasive Wrinkle Reduction and Lifting Technology in Mexico — the Second Largest Aesthetic Medical Market in Latin America
Sofwave Market Approvals For SUPERB™ Non-Invasive Wrinkle Reduction Technology Now Extend to Taiwan
growth-positive
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Cellulite
SofWave Medical Ltd has received FDA clearance for its SUPERB™ technology to be used for the short-term improvement in the appearance of cellulite. The company conducted a multi-site clinical study that evaluated the safety and effectiveness of the device for non-invasive dermatological aesthetic improvement in cellulite appearance. The FDA clearance comes at a timely moment as SofWaves U.S. direct sales force is positioned to expand its presence and market share in the aesthetic medical device market. The company also recently received regulatory clearance in Brazil and has a partnership in China to further extend its global footprint. SofWaves SUPERB™ technology is also cleared by the FDA for other indications such as lifting the eyebrow, lifting lax submental tissue, and improving facial lines and wrinkles.
CustomersPartners
growth-positive
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Cellulite
SofWave Medical Ltd has received FDA clearance for its SUPERB™ technology to be used for the short-term improvement in the appearance of cellulite. The company conducted a multi-site clinical study that evaluated the safety and effectiveness of the device for non-invasive dermatological aesthetic improvement in cellulite appearance. The companys CEO, Lou Scafuri, stated that the clearance could not have come at a better time as the company is positioned to expand its growing presence and market share of the aesthetic medical device market in the U.S. and globally.
InvestmentPartnersExpand
Sofwave Medical Reports Third Quarter 2022 Financial Results and Business Highlights
Sofwave Gains Approval to Market the SUPERB™ Non-Invasive Wrinkle Reduction Device in Brazil
growth-positive
Sofwave™ Granted U.S. Patent Covering Key Elements of the Company's Proprietary SUPERB™ Non-Surgical Skin and Collagen Remodeling Technology
SofWave Medical has been granted a patent by the U.S. Patent and Trademark Office for its SUPERB™ technology, which uses ultrasound energy and cooling to safely remodel collagen in the skin. The patent protects the transducer array and cooling module used in the technology. This is the companys first U.S. patent, in addition to existing patents in China and Hong Kong. SofWave Medical has 29 additional patents pending globally. The technology is a non-invasive alternative to invasive skin resurfacing treatments and has been FDA-cleared for wrinkle reduction and lifting. SofWave Medical continues to focus on building its intellectual property portfolio.
PartnersInvestment
Sofwave™ Granted U.S. Patent Covering Key Elements of the Company’s Proprietary SUPERB™ Non-Surgical Skin and Collagen Remodeling Technology
Sofwave Participate in LifeSci Partners HealthTech Symposium
Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and Dermatology Conference
growth-positive
Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and Dermatology Conference
Sofwave Medical Ltd. will be participating in the 5CC World Congress, a conference focused on medical dermatology and aesthetic treatments. The company will have a showcase booth, conduct a treatment workshop, and hold speaking sessions on its SUPERB technology for lifting skin in various areas. The conference will take place from September 1-4 in Barcelona, Spain. Sofwave Medical specializes in energy-based non-invasive aesthetic medical devices and provides smart and effective solutions for wrinkle reduction and lifting. The companys Synchronous Ultrasound Parallel Beam technology is FDA-cleared and has been proven to improve facial lines and wrinkles, lift the eyebrow, and tighten submental and neck tissue.
PartnersCustomers
Sofwave Medical Reports First Half Financial Results and Business Highlights
growth-positive
Sofwave Medical Reports First Half Financial Results and Business Highlights
Sofwave Medical Ltd reported a 34% YoY increase in revenue for the first half of fiscal year 2022. They also saw a significant increase in recurring revenue and signed a key agreement with a major partner in China. The companys CEO highlighted the success of their SUPERB lifting and wrinkle reduction technology and the adoption of their devices by top-ranking providers. Sofwave also completed patient enrollment in a clinical trial for the treatment of cellulite. They have expanded their social media following and made additions to their leadership and sales positions. The company aims to broaden the clinical indications of their technology and expects it to significantly expand revenue streams for physicians. Financially, Sofwave reported a gross profit of $10.1 million and an operating loss of $9.0 million for the first half of 2022.
CustomersPartners
Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China’s Growing $29 Billion Aesthetic Medicine Market
growth-positive
Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China's Growing $29 Billion Aesthetic Medicine Market
SofWave Medical has entered a collaboration and distribution agreement with HTDK Group to advance its sales in China. HTDK Group will help SofWave accelerate its product registration approval with Chinas National Medical Products Administration (NMPA) and support its product marketing, distribution, and sales in China. The partnership aims to tap into Chinas rapidly growing medical aesthetic market, which is projected to have a double-digit compounded annual growth rate. HTDK Group is a leading commercialization solutions provider owned by Warburg Pincus, a global growth investor. The partnership is expected to support SofWaves market entry and business success in China.
Partners
growth-positive
SOFWAVE™ TECHNOLOGY WINS MAJOR BEAUTY AWARDS -- 2022 ADDING TO THE 2021 ELLE AWARD
Sofwave Medical Ltd has received multiple beauty awards for its game-changing ultrasound technology to revitalize the skin. The company was honored with awards from Cosmopolitan, NewBeauty, ELLE, and SHAPE. These awards recognize Sofwave as a leader in energy-based non-invasive aesthetic medical devices. The companys reach is expanding, and it has gained recognition in popular publications. Sofwave technology has been well-received by physicians and consumers, and the company is exceeding its goals in penetrating the consumer market. Sofwave Medical will continue to develop innovative products to meet the needs of its customers and their patients.
Customers
growth-positive
Sofwave Medical LTD reports financial results for the full year 2021 with accelerated growth in revenues and gross margin
Sofwave, an aesthetic device company, reported a sharp increase in revenue to $21.8 million in 2021, up from $4.3 million in 2020. The company also reported record Q4 2021 revenues of $8.9 million. The growth was attributed to the companys accelerated growth plans in the North American market and the opening of additional markets in Asia and Europe. Sofwave also received FDA approval for additional indications for lifting the eyebrow, sub-mental, and facial neck areas. The company made its initial public offering on the Tel-Aviv Stock Exchange in May 2021.
CustomersPublic TradingExpand
growth-positive
Sofwave™ Awarded Elle Magazine's 2021 Future of Beauty Awards!
Sofwave Medical Ltd has been honored with Elle Magazines 2021 Future of Beauty Awards and recognized as one of the best in the In-Office Skin Treatment Category. The companys breakthrough technology, Sofwave™ Synchronous Ultrasound Parallel Beam, has received FDA clearance for lifting the eyebrow, submental, and neck, as well as reducing fine lines and wrinkles. The award validates Sofwaves exceptional results and innovative products in the medical aesthetics industry. Sofwave Medical Ltd aims to meet the needs of its customers and their patients by developing advanced aesthetic solutions. The article does not mention any specific partners, customers, valuation amount, layoffs, or investment amount. The event described in the article occurred on December 13, 2021.
Customers
growth-positive
Sofwave™ Announces FDA clearance of New Lifting Indications for Eyebrow, Sub-Mental (beneath the chin) and Neck Facial Areas
Sofwave Medical Ltd announces FDA clearance of additional indications for its non-invasive dermatological aesthetic treatment. The clearance includes lifting the eyebrow and lifting lax submental tissue and neck tissue. The companys proprietary technology, SUPERB TM, is also cleared for improving facial lines and wrinkles. The clearance is a major achievement for Sofwave Medical and demonstrates their focus on innovation and clinical advancements. The company conducted a multi-site clinical study to support the expansion of indications. Sofwave Medical aims to provide effective and safe aesthetic solutions for physicians and their patients.
Customers
growth-positive
Sofwave™ Medical Raises $50M and Completes Initial Public Offering on the Tel Aviv Stock Exchange
Sofwave Medical, a medical aesthetic company, raised $50 million in an initial public offering (IPO) on the Tel Aviv Stock Exchange. The companys innovative approach to wrinkle reduction using its Synchronous Ultrasound Parallel Beam Technology has led to rapid market adoption. The IPO raised $50 million at a pre-money valuation of approximately $200 million. Sofwave Medical is listed on TASE and its product is FDA cleared with sales across global markets. The IPO provides an opportunity for global investors to participate in the growth potential of the aesthetic medicine field. The company plans to utilize the proceeds to expand its commercial efforts and indications for use of its technology.
Public TradingInvestment
growth-positive
סופווייב מדיקל הונפקה בתל אביב - וגייסה 50 מיליון דולר
Sofwave Medical, a company that develops and markets technology for wrinkle treatment and skin rejuvenation, has begun trading on the Tel Aviv Stock Exchange with a value of approximately 800 million shekels ($245 million). The company raised $50 million in funding led by Barclays Capital and Leumi Partners. Sofwave Medicals unique technology for wrinkle smoothing and skin tightening has gained significant attention in the market.
Public Trading
growth-positive
סופווייב נהנתה מביקושים של יותר מפי שניים; תתחיל להיסחר בתל אביב בשבוע הבא כלכליסט
SofWave Medical, a company that develops and markets technology for smoothing skin wrinkles, has successfully completed its IPO process on the Tel Aviv Stock Exchange. The company raised about $50 million (165 million shekels) from institutional investors, based on a company value of about $192 million, so the final value in the issuance stands at about 800 million shekels. The company is expected to start trading next Tuesday. The companys product, which it has already started selling worldwide, is based on technology that allows non-invasive treatment using ultrasound to smooth wrinkles and tighten facial and neck skin.
InvestmentPublic Trading
growth-positive
Skin treatment co Sofwave files to raise $50m on TASE
Israeli aesthetic medicine company Sofwave has filed a prospectus for an IPO on the Tel Aviv Stock Exchange. The company aims to raise $50 million at a valuation of $200 million. Sofwave, founded in 2015, is developing an ultrasound skin treatment for wrinkles. The IPO is being led by Barak Capital Underwriters. Sofwaves product is FDA approved and sales have already begun in the US. The company has also obtained the EU CE mark. The founder, Dr. Shimon Eckhouse, has a history of successful exits from previous companies in the aesthetics and medical device industries. Sofwave previously raised $8.4 million in a financing round. The event described in the article occurred on April 19, 2021.
Public TradingInvestment
growth-positive
Sofwave Receives Australian Regulatory Approval to Market SUPERB™, the Breakthrough Ultrasound Technology Treating Fine Lines & Wrinkles
Sofwave Medical has received approval from Australias Therapeutic Goods Administration for its next-generation Sofwave system, which offers noticeable wrinkle reduction in a single treatment. The company aims to expand its international product reach and meet the growing demand for non-invasive treatments. Sofwaves Synchronous Ultrasound Parallel Beam technology addresses this demand by delivering parallel energy simultaneously to improve the appearance of facial wrinkles. The treatment is fast, non-invasive, and causes no post-treatment discomfort. Sofwave Medical is focused on providing innovative and safe aesthetic solutions for physicians and their patients.
CustomersPartners
growth-positive
Skin treatment co Sofwave plans TASE IPO
Israeli aesthetic medicine company Sofwave plans to raise capital through an IPO on the Tel Aviv Stock Exchange. The company, which has developed ultrasound technology for wrinkles, aims to raise several tens of millions of dollars at a company valuation of $200 million. The IPO is being led by Barak Capital Underwriters. Sofwaves product is FDA approved and sales have already begun in the US, with the company also having the EU CE mark. Sofwave was founded in 2015 in Dr. Shimon Eckhouses Alon Medtech Ventures incubator.
InvestmentPublic Trading
growth-positive
Sofwave receives CE Medical Mark and additional key Regulatory Clearances for its Revolutionary Skin Tightening and Wrinkle Reduction Device
Sofwave Medical has secured CE Mark for its next-generation Sofwave system, which is approved for the treatment of fine lines and wrinkles in the EU. The company also received regulatory approval from the Medical Device Division of the Israeli Ministry of Health. Sofwaves technology addresses the growing demand for non-invasive treatments that improve skin laxity and reduce wrinkles. The company plans to launch its commercialization efforts in Israel and has placed its first unit with Professor Eyal Gur at the Tel Aviv Sourasky Medical Center. Sofwave aims to expand its commercial footprint outside the U.S. by securing product registrations and distribution partners in international markets.
CustomersPartners
growth-positive
First Two Doctors in Arizona to Offer Sofwave™ Newest Non-invasive Treatment to Hit the Market for Fine Lines and Wrinkles on Face & Neck
Sofwave Medical Ltd., an emerging aesthetic company, has developed the Sofwave ultrasound system for improving fine lines and wrinkles on the face and neck. Two physicians in Arizona, Daniel Shapiro and Zaina Rashid, are the first to offer this technology to their patients. The Sofwave system has received FDA clearance and has shown significant improvement in 87% of patients after a single treatment. The treatment is non-invasive and requires no downtime. Sofwave Medical Ltd. aims to provide physicians with effective and safe aesthetic solutions. Dr. Shapiro and Dr. Rashid are renowned plastic surgeons who have achieved national recognition for their results.
Partners
growth-positive
Arielle Kauvar, M.D., Announces New Technology to Improve Fine Lines and Wrinkles on the Face and Neck with Successful Clinical Study Pivotal to Sofwave's™ FDA 510K Clearance.
Dr. Arielle Kauvar, the founding director of New York Laser & Skin Care, conducted clinical studies for Sofwave, a new ultrasound treatment for fine lines and wrinkles. The studies resulted in FDA 510K clearance for Sofwave. The treatment has shown significant improvement in 87% of patients after a single session. New York Laser & Skin Care is one of the first dermatology practices in the US to offer Sofwave. Sofwave utilizes proprietary Intense Ultrasound Beam technology and provides effective treatment with no downtime.
Customers
growth-positive
SofWave Medical's Low-divergence Ultrasound Technology Has Received FDA Clearance for the Aesthetic Treatment of Facial Lines and Wrinkles
Sofwave Medical Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Sofwave system, a non-invasive aesthetic treatment to improve facial lines and wrinkles. The clearance was supported by a study of 59 subjects, showing safety and performance. The company plans to launch marketing and sales activities in the United States and has established an office there. Sofwave Medicals breakthrough technology brings a new option to non-invasive aesthetic treatments.
CustomersPartnersInvestmentExpand
growth-positive
Skin tightening cosmetic co SofWave Medical raises $8.4m
Israeli aesthetic medical company SofWave Medical Ltd. has closed an $8.4 million financing round led by XT Hi-Tech and Dr. Shimon Eckhouse. The company has developed non-invasive fractional ultrasound technology for skin tightening. SofWave Medical also announced the appointment of Louis Scafuri as the companys CEO. The financing round will enable the company to build and position itself as a leader in the aesthetic medical market.
InvestmentManagement Changes
Sofwave Medical Team
Carmit Meirnovski
Employee Info
| Employees (range) | 51-200 |
| Exact count | 188 |
| Team members | 8 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Sofwave Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 101/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 515198158 |
| Creator | Sofwave Sofwave |
| Creator email | sofwavemarketing@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-06-03T00:00:00.000Z |
| Created | 2020-08-03T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on TASE on May, 2021<br> |